Fei Hong

Fei Hong

Auto-generated profile, based on publicly available information

Fei Hong

Department of Hematology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
FHFei Hong
Fei Hong
MSMing Shi
Ming Shi
JCJiang Cao
Jiang Cao
YWYing Wang
Ying Wang
YGYanqing Gong
Yanqing Gong
KXKailin Xu
Kailin Xu
CD19‐target chimeric antigen receptor (CAR)‐T cell therapy is highly effective for relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL), but is often complicated by cytokine release syndrome (CRS), which is potentially life‐threatening. Endothelial cells are the core regulator of CRS in many infectious diseases and may also play a key role after CAR‐T cell therapy. We provided a detailed clinical, laboratory description and endothelial cell activation biomarkers in patients with CRS. Endothelial cell activation was associated with occurrence, development and severity of CRS, manifested by decreased serum angiopoietin (Ang)‐1 levels and increased levels of von Willebrand Factor (VWF), Ang‐2, Ang‐2:Ang‐1, sE‐selectin, soluble intercellular adhesion molecule (sICAM‐1) and soluble vascular cell adhesion molecule (sVCAM)‐1. Besides, the endothelial activation was correlated with the hepatic, kidney and hematopoietic dysfunction in CRS patients. After infusion of CAR‐T cells, we detected changes of endothelial activation‐related biomarkers within 36 hours in patients who subsequently developed CRS, especially severe CRS. Using top tree models, we could predict which patients would develop CRS, especially severe CRS, or identify the severity of CRS by certain biomarkers of endothelial activation. These data provide a new idea and will help identify new targets for early intervention and prevention of CRS.

25 April 2023 in Hematological Oncology
Verified
Journal Article
Closed access
RLRui Liu
Rui Liu
YLYang Lv
Yang Lv
FHFei Hong
Fei Hong
WZWanhong Zhao
Wanhong Zhao
BLBo Lei
Bo Lei
FWFangxia Wang
Fangxia Wang